Subtype diagnosis included luminal breast cancer (n = 14, 45.1%), HER2-positive breast cancer (n = 9, 29.0%), and triple-negative breast cancer (n = 8, 25.8%). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.